🔗 Visit the ClinicalTrials.gov page for NCT01718353
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. | Endocr Relat Cancer | 2014 | 1.45 |
| 2 | Perspectives on treatment of metastatic castration-resistant prostate cancer. | Oncologist | 2013 | 1.42 |
| 3 | Castration-resistant prostate cancer: latest evidence and therapeutic implications. | Ther Adv Med Oncol | 2014 | 1.11 |
| 4 | Chemotherapy and its evolving role in the management of advanced prostate cancer. | Asian J Androl | 2014 | 0.88 |
| 5 | The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. | Ther Adv Urol | 2014 | 0.83 |
| 6 | Using circulating tumor cells to inform on prostate cancer biology and clinical utility. | Crit Rev Clin Lab Sci | 2015 | 0.80 |
| 7 | Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. | Mol Diagn Ther | 2014 | 0.79 |